Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DM8YU2F)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
Cantil; Cantilaque; Cantilon; Cantril; Colibantil; Colopiril; Colum; Delevil; Eftoron; Gastropidil; Glycophenylate; Mepenzolon; Tralanta; Trancolon; Trokonil; Bromure de mepenzolate; Bromuro de mepenzolato; MEPENZOLATE BROMIDE; Mepenzolate Methylbromide; Mepenzolati bromidum; Mepenzolic acid; Mepenzolone Bromide; JB 340; Bromure de mepenzolate [INN-French]; Bromuro de mepenzolato [INN-Spanish]; Cantil (TN); Mepenzolati bromidum [INN-Latin]; Mepenzolic acid, bromine salt; Mepenzolate bromide (JP15/INN); Mepenzolate bromide [INN:BAN:JAN]; N-Methyl-3-piperidyl benzilate methobromide; N-Methyl-3-piperidyl benzilate methyl bromide; N-Methyl-3-piperidyldiphenylglycolate methobromide; N-methyl-3-piperidylbenzilate methyl bromide; Benzilic acid, 1-methyl-3-piperidyl ester methobromide; Benzilic acid, ester with 3-hydroxy-1,1-dimethylpiperidinium bromide; Piperidinium, 3-[(hydroxydiphenylacetyl)oxy]-1,1-dimethyl-, bromide; Piperidinium, 3-hydroxy-1,1-dimethyl-, benzilate (ester); Piperidinium, 3-hydroxy-1,1-dimethyl-, bromide, benzilate; Piperidinium, 3-((hydroxydiphenylacetyl)oxy)-1,1-dimethyl-(VAN); Piperidinium, 3-((hydroxydiphenylacetyl)oxy)-1,1-dimethyl-, bromide; (1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate; (1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate bromide; 1-Methyl-3-piperidyl benzilate methyl bromide; 1-Methyl-3-piperidyl benzilate methylbromide; 2-(1,1-dimethylpiperidin-1-ium-3-yl)oxy-2-oxo-1,1-diphenylethanolate; 2-[(1,1-dimethylpiperidinium-3-yl)oxy]-2-oxo-1,1-diphenylethanolate; 3-((Hydroxydiphenylacetyl)oxy)-1,1-dimethylpiperidinium bromide; 3-Hydroxy-1,1-dimethylpiperidinium bromide benzilate; 3-{[hydroxy(diphenyl)acetyl]oxy}-1,1-dimethylpiperidinium bromide
| |||||
| Therapeutic Class | Parasympatholytics | |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Bone
Osteosarcoma
Breast
Breast adenocarcinoma
Prostate
Prostate carcinoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||